Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
By incorporating Semaglutide GLP-1 into your treatment plan, you can take a step closer to achieving your health goals, with the support of a skilled professional dedicated to your long-term success
But why was semaglutide chosen for FDA approval over compounded alternatives
According to a recent KFF poll, 12% of adults say they have taken a GLP-1
In another study, Metwally et al
Approximately 750 of those 902 participants who completed the 20-week introductory period were randomly assigned to either continue to receive the same dosage or a placebo for an extra 48 weeks